AstraZeneca (AZN) said Friday that its late-stage trial of its therapy, Imfinzi, when combined with standard BCG induction and maintenance therapy, showed significantly improved disease-free survival in patients with high-risk non-muscle-invasive bladder cancer.
The company said the trial was not statistically powered to formally test overall survival but a descriptive analysis demonstrated no detriment.
The drugmaker said the therapy did not raise new safety concerns and did not compromise patients' ability to complete BCG induction and maintenance therapy.
A second experimental arm evaluating Imfinzi combined with BCG induction-only therapy compared to BCG induction and maintenance therapy alone failed to meet the endpoint of disease-free survival, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。